pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Sionna Therapeutics, Inc. ($SION) · news · pharmadog
← back to Sionna Therapeutics, Inc.
News mentioning $SION
81
stories
21h
Epic's AI push overlaps with health tech startups
endpoints
1d
FDA pick Heidi Overton has been critical of vaccine requirements, abortion pills
endpoints
2d
Trump to pick Heidi Overton to lead the FDA
endpoints
2d
Epic is under pressure
endpoints
7d
'Incorrect and misleading' data prompted decision to pull Tavneos in Europe
endpoints
7d
Karyopharm has a month left to salvage its cancer expansion plans
endpoints
10d
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
biopharma dive
10d
Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex
endpoints
10d
Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise
biospace
10d
STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
stat
11d
Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex
fiercebiotech
16d
The China Debate: Biotech deserves a deeper discussion
endpoints
16d
Vertex’s biggest overhang: a rival 50 times smaller
biopharma dive
16d
Otsuka succeeds with kidney drug; BioNTech downgrades revenue projection
endpoints
17d
Work ethic becomes a flashpoint as China's biotech pace quickens
endpoints
20d
Pharma groups back changes to 340B rebate pilot
endpoints
20d
Ionis' top scientist Frank Bennett to retire; Recursion selects its first AI chief
endpoints
22d
FTC sues Hims for sharing sensitive health information, billing practices
endpoints
22d
Former Recursion CEO Chris Gibson joins Dimension as operating partner
endpoints
27d
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs
endpoints
28d
Sartorius reduces revenue by €26M to refund Trump tariffs to customers
endpoints
28d
Repligen’s $1.5B buy for BioLife; BeOne’s $300M US expansion
endpoints
29d
FDA swiftly puts Makary era in the rearview mirror
endpoints
29d
Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM deal
endpoints
Jul 21, 26
FDA plans to name permanent center heads alongside FDA chief
endpoints
Jul 21, 26
Gilead and Merck provide HIV data; Dimension Capital announces $800M fund
endpoints
Jul 17, 26
Dimerix buys a kidney injury drug; Arpeggio appears to be winding down
endpoints
Jul 15, 26
FDA acting chief walks back Makary's practice of policymaking through journals
endpoints
Jul 14, 26
Draig nets $65M to advance depression drug aimed at rebuilding synapses
endpoints
Jul 9, 26
Roche ends work on tominersen after decade of trials, as well as early-stage Huntington’s asset
endpoints
← prev
page 1 of 3
next →
